ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of standard treatments

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503068-34-00

Acronym

ET19-075

Enrollment

110

Registered

2024-01-15

Start date

2022-04-06

Completion date

Unknown

Last updated

2025-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor, Unresectable Gastrointestinal Stromal Tumor (GIST)

Brief summary

Progression-Free Survival

Detailed description

1.Best Response Rate, 2.Objective Response Rate, 3.Time to Treatment Failure, 4.Overall Survival, 5.Quality of Life 6.Tolerability profile

Interventions

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGIMATINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival	—

Secondary

Measure	Time frame
1.Best Response Rate, 2.Objective Response Rate, 3.Time to Treatment Failure, 4.Overall Survival, 5.Quality of Life 6.Tolerability profile	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026